Lantheus Holdings Inc
LNTH73.880USD
-0.530-0.71%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
5.11BCap. mercado
20.09P/E TTM
Más Datos de Lantheus Holdings Inc Compañía
Lantheus Holdings, Inc. is a radiopharmaceutical-focused company engaged in delivering science to enable clinicians to find, fight and follow diseases to deliver patient outcomes. It classifies its products in three categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships. Radiopharmaceutical Oncology diagnostics and therapeutics help healthcare professionals (HCPs) find, fight and follow cancer, with a focus on prostate cancer. Precision Diagnostic products assist HCPs to find and follow diseases, with a focus on cardiology. Strategic Partnerships focus on enabling precision medicine through the use of biomarker solutions, digital solutions, and radiotherapeutic platforms. Its commercial products include PYLARIFY, DEFINITY, TechneLite, and others. Its clinical candidates include LNTH-2404, NAV-4694, and PNT2002, others. Its OCTEVY is a registrational-stage positron emission tomography (PET) diagnostic imaging agent targeting neuroendocrine tumors.
Información de la empresa
Símbolo de cotizaciónLNTH
Nombre de la empresaLantheus Holdings Inc
Fecha de salida a bolsaJun 25, 2015
Fundada en2007
Director ejecutivoMr. Brian A. Markison
Número de empleados808
Tipo de seguridadOrdinary Share
Fin del año fiscalJun 25
Dirección331 Treble Cove Road
CiudadNORTH BILLERICA
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal01862
Teléfono19786718001
Sitio Webhttps://www.lantheus.com/
Símbolo de cotizaciónLNTH
Fecha de salida a bolsaJun 25, 2015
Fundada en2007
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Mary Anne Heino
Ms. Mary Anne Heino
Chairman of the Board
Chairman of the Board
584.72K
-4.27%
Mr. Brian A. Markison
Mr. Brian A. Markison
Chief Executive Officer, Director
Chief Executive Officer, Director
232.42K
+35.31%
Ms. Amanda Morgan
Ms. Amanda Morgan
Chief Commercial Officer
Chief Commercial Officer
39.58K
+55.76%
Dr. Jean-Claude Provost, M.D.
Dr. Jean-Claude Provost, M.D.
Chief Scientific Officer
Chief Scientific Officer
38.84K
-31.55%
Dr. James H. (Jim) Thrall
Dr. James H. (Jim) Thrall
Independent Director
Independent Director
35.74K
+7.64%
Ms. Julie H. Mchugh
Ms. Julie H. Mchugh
Lead Independent Director
Lead Independent Director
25.96K
-16.67%
Dr. Gerard Ber, Ph.D.
Dr. Gerard Ber, Ph.D.
Independent Director
Independent Director
23.36K
+10.09%
Ms. Minnie Baylor-Henry, J.D.
Ms. Minnie Baylor-Henry, J.D.
Independent Director
Independent Director
9.90K
+34.47%
Dr. Phuong Khanh (P. K.) Morrow, M.D.
Dr. Phuong Khanh (P. K.) Morrow, M.D.
Independent Director
Independent Director
3.10K
+450.62%
Mr. Samuel R. (Sam) Leno
Mr. Samuel R. (Sam) Leno
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Mary Anne Heino
Ms. Mary Anne Heino
Chairman of the Board
Chairman of the Board
584.72K
-4.27%
Mr. Brian A. Markison
Mr. Brian A. Markison
Chief Executive Officer, Director
Chief Executive Officer, Director
232.42K
+35.31%
Ms. Amanda Morgan
Ms. Amanda Morgan
Chief Commercial Officer
Chief Commercial Officer
39.58K
+55.76%
Dr. Jean-Claude Provost, M.D.
Dr. Jean-Claude Provost, M.D.
Chief Scientific Officer
Chief Scientific Officer
38.84K
-31.55%
Dr. James H. (Jim) Thrall
Dr. James H. (Jim) Thrall
Independent Director
Independent Director
35.74K
+7.64%
Ms. Julie H. Mchugh
Ms. Julie H. Mchugh
Lead Independent Director
Lead Independent Director
25.96K
-16.67%
Desglose de ingresos
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Por negocioUSD
Nombre
Ganancia
Proporción
PYLARIFY
257.65M
0.00%
DEFINITY
79.21M
0.00%
TechneLite
19.71M
0.00%
Strategic partnerships and other
10.75M
0.00%
Other precision diagnostics
5.44M
0.00%
Radiopharmaceutical oncology
0.00
0.00%
Sin datos
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
PYLARIFY
257.65M
0.00%
DEFINITY
79.21M
0.00%
TechneLite
19.71M
0.00%
Strategic partnerships and other
10.75M
0.00%
Other precision diagnostics
5.44M
0.00%
Radiopharmaceutical oncology
0.00
0.00%
Estadísticas de accionistas
Actualizado: mié., 14 de may
Actualizado: mié., 14 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
BlackRock Institutional Trust Company, N.A.
11.27%
The Vanguard Group, Inc.
10.10%
Janus Henderson Investors
9.05%
Farallon Capital Management, L.L.C.
8.71%
State Street Global Advisors (US)
3.81%
Other
57.07%
Accionistas
Accionistas
Proporción
BlackRock Institutional Trust Company, N.A.
11.27%
The Vanguard Group, Inc.
10.10%
Janus Henderson Investors
9.05%
Farallon Capital Management, L.L.C.
8.71%
State Street Global Advisors (US)
3.81%
Other
57.07%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor/Hedge Fund
53.47%
Investment Advisor
43.79%
Hedge Fund
11.55%
Research Firm
3.19%
Individual Investor
2.27%
Pension Fund
1.94%
Bank and Trust
1.35%
Sovereign Wealth Fund
0.57%
Family Office
0.09%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
1027
81.92M
118.40%
-3.35M
2025Q1
1066
83.20M
120.27%
-2.89M
2024Q4
1033
78.65M
114.86%
-4.64M
2024Q3
1003
73.69M
106.06%
-7.92M
2024Q2
959
71.82M
103.63%
-10.29M
2024Q1
912
71.21M
103.87%
-11.25M
2023Q4
868
73.50M
107.32%
-9.24M
2023Q3
828
74.80M
109.31%
-3.81M
2023Q2
790
72.85M
106.61%
-3.94M
2023Q1
733
71.94M
105.47%
-6.73M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
BlackRock Institutional Trust Company, N.A.
7.79M
11.27%
+17.69K
+0.23%
Mar 31, 2025
The Vanguard Group, Inc.
6.99M
10.1%
-242.63K
-3.36%
Mar 31, 2025
Janus Henderson Investors
6.26M
9.05%
-252.58K
-3.88%
May 30, 2025
Farallon Capital Management, L.L.C.
6.02M
8.71%
+707.00K
+13.30%
Mar 31, 2025
State Street Global Advisors (US)
2.64M
3.81%
-4.26K
-0.16%
Mar 31, 2025
Fidelity Management & Research Company LLC
2.17M
3.14%
+148.84K
+7.36%
Mar 31, 2025
Geode Capital Management, L.L.C.
1.78M
2.57%
+94.57K
+5.62%
Mar 31, 2025
Westfield Capital Management Company, L.P.
1.59M
2.3%
+34.05K
+2.19%
Mar 31, 2025
T. Rowe Price Investment Management, Inc.
1.41M
2.04%
-96.91K
-6.42%
Mar 31, 2025
Reinhart Partners, LLC
1.21M
1.74%
-160.93K
-11.77%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: dom., 6 de jul
Actualizado: dom., 6 de jul
Nombre
Proporción
Harbor Health Care ETF
2.88%
Invesco S&P MidCap 400 GARP ETF
2.64%
Invesco Dorsey Wright Healthcare Momentum ETF
2.28%
SPDR S&P Health Care Equipment ETF
1.83%
Fidelity Stocks for Inflation ETF
1.32%
Janus Henderson US Sustainable Equity ETF
1.26%
Invesco S&P MidCap 400 Pure Growth ETF
1.06%
First Trust Small Cap US Equity Select ETF
1%
Astoria US Quality Kings ETF
0.78%
VictoryShares Free Cash Flow Growth ETF
0.74%
Ver más
Harbor Health Care ETF
Proporción2.88%
Invesco S&P MidCap 400 GARP ETF
Proporción2.64%
Invesco Dorsey Wright Healthcare Momentum ETF
Proporción2.28%
SPDR S&P Health Care Equipment ETF
Proporción1.83%
Fidelity Stocks for Inflation ETF
Proporción1.32%
Janus Henderson US Sustainable Equity ETF
Proporción1.26%
Invesco S&P MidCap 400 Pure Growth ETF
Proporción1.06%
First Trust Small Cap US Equity Select ETF
Proporción1%
Astoria US Quality Kings ETF
Proporción0.78%
VictoryShares Free Cash Flow Growth ETF
Proporción0.74%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
